|
IGA Glomerulonephritis
|
0.410 |
GeneticVariation
|
disease |
BEFREE |
Previous genome wide association studies (GWAS) reported that variants CARD9 and VAV3 genes were associated with immunoregulation and susceptibility to IgAN.
|
29100328 |
2017 |
|
IGA Glomerulonephritis
|
0.410 |
Biomarker
|
disease |
CTD_human |
Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens.
|
25305756 |
2014 |
|
IGA Glomerulonephritis
|
0.410 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens.
|
25305756 |
2014 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that Vav3 plays a crucial role in prostate cancer growth and malignant behavior, thus revealing a novel potential therapeutic target.
|
23403204 |
2014 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Vav3 enhances androgen receptor (AR) activity during progression to androgen independence in prostate cancer.
|
23566222 |
2013 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Vav3, a Rho GTPase guanine nucleotide exchange factor (GEF), is overexpressed in human prostate cancers, particularly in models of CRPC progression.
|
21765461 |
2012 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, our findings provide evidence that the Vav3-mediated signaling pathway may serve as a therapeutic target for prostate cancer metastasis.
|
22659453 |
2012 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Vav3, a Rho GTPase guanine nucleotide exchange factor, is an AR coactivator that is up-regulated in human prostate cancer compared with benign tissue and in preclinical models of CRPC.
|
23023561 |
2012 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data revealed that Vav3 overexpression as an additional underlying mechanism contributes to elevated sPLA2-IIa expression in prostate cancer.
|
21455584 |
2011 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our previous study revealed that Vav3 oncogene is overexpressed in human prostate cancer, activates androgen receptor, and stimulates growth in prostate cancer cells.
|
18518979 |
2008 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because Vav3 may be chronically activated in prostate cancer by growth factor receptors, we examined the effects of a constitutively active (Ca) form of Vav3 on AR transcriptional activity.
|
18079321 |
2008 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
CTD_human |
We found that prostate tumors from the Low-T mutant mice share a similar gene expression profile as androgen-independent prostate tumors from these mutant mice, which includes the deregulated expression of several genes that are up-regulated in human hormone-refractory prostate cancer, such as Vav3 and Runx1.
|
17909013 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Vav3 expression was also detected in other human prostate cancer cell lines (PC-3, DU145, and 22Rv1) and, by immunohistochemistry analysis, was detected in 32% (26 of 82) of surgical specimens of human prostate cancer.
|
16762975 |
2006 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We observed a marked increase in the expression of Vav3, a Rho GTPase guanine nucleotide exchange factor (GEF), during the progression of human prostate cancer LNCaP cells to the androgen-independent derivative, LNCaP-R1.
|
16384856 |
2006 |
|
Hypertensive disease
|
0.320 |
GeneticVariation
|
group |
BEFREE |
On the other hand, being carrier of the T allele in VAV3 rs7528153 polymorphism is associated with a decreased susceptibility of developing a pathologic state composed by the presence of hypertension, diabetes, obesity or cardiovascular damage, and with an increased risk of developing altered basal glycaemia.
|
28157227 |
2017 |
|
Hypertensive disease
|
0.320 |
GeneticVariation
|
group |
BEFREE |
The study objectives were to analyse the relationship of TOD to blood pressure, size of retinal arteries and veins, oxidative stress and different polymorphisms in the VAV-2 and VAV-3 genes in participants with hypertension.
|
24699462 |
2014 |
|
Hypertensive disease
|
0.320 |
Biomarker
|
group |
CTD_human |
We also report that Ahr- and Vav3-deficient mice display hypertension, tachypnea, and sympathoexcitation.
|
21115475 |
2011 |
|
Prostatic Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
We found that prostate tumors from the Low-T mutant mice share a similar gene expression profile as androgen-independent prostate tumors from these mutant mice, which includes the deregulated expression of several genes that are up-regulated in human hormone-refractory prostate cancer, such as Vav3 and Runx1.
|
17909013 |
2007 |
|
Prostatic Neoplasms
|
0.320 |
AlteredExpression
|
group |
LHGDN |
Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
|
16384856 |
2006 |
|
Prostatic Neoplasms
|
0.320 |
AlteredExpression
|
group |
LHGDN |
Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
|
16762975 |
2006 |
|
Hyperventilation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Transcriptional factor aryl hydrocarbon receptor (Ahr) controls cardiovascular and respiratory functions by regulating the expression of the Vav3 proto-oncogene.
|
21115475 |
2011 |
|
Tachycardia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Transcriptional factor aryl hydrocarbon receptor (Ahr) controls cardiovascular and respiratory functions by regulating the expression of the Vav3 proto-oncogene.
|
21115475 |
2011 |
|
Tachyarrhythmia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Transcriptional factor aryl hydrocarbon receptor (Ahr) controls cardiovascular and respiratory functions by regulating the expression of the Vav3 proto-oncogene.
|
21115475 |
2011 |
|
Autoimmune Diseases
|
0.110 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Hypothyroidism
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |